Isosorbide mononitrate
(Synonyms: 单硝酸异山梨酯; Isosorbide-5-mononitrate) 目录号 : GC36346
A nitric oxide donor with cardioprotective activity
Cas No.:16051-77-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Isosorbide mononitrate (ISMN) is a nitric oxide (NO) donor with cardioprotective activity.1,2,3 It induces relaxation of precontracted isolated rat mesenteric artery rings with and without endothelium (EC50s = 87 and 30.1 ?M, respectively).1 ISMN (150 mg/kg) prevents increases in blood pressure and plasma levels of thromboxane A2 (TXA2), as well as reduces platelet aggregation in a rat model of hypertension induced by cyclosporin A when administered prior to CsA.2 However, ISMN exacerbates the CsA-induced cardiac phenotype in rats when administered seven weeks after initial CsA administration. ISMN (200 mg/kg) decreases aortic superoxide production, reduces intima-media thickness of the thoracic aorta, and improves endothelium-dependent vasorelaxation in a rabbit model of cholesterol-enriched diet-induced atherosclerosis.3 It also prolongs survival time of mice in a normobaric hypoxia test.4 Formulations containing ISMN have been used in the treatment of angina in patients with coronary artery disease.
1.Stepanovi?-Petrovi?, R.M., V., S., Tomi?, M.A., et al.Comparison of vasorelaxant effect and tolerance profile of a novel isosorbide-5-mononitrate derivative with its stereoisomer and parent drug on rat mesenteric arteryArznei-forschung60(4)189-197(2010) 2.Reis, F., Ponte, L., Teixeira-Lemos, E., et al.Curative isosorbide-5-mononitrate treatment, in opposition to the beneficial preventive one, aggravates the prothrombotic and proconstrictor state in cyclosporine-induced hypertensive ratsClin. Exp. Pharmacol. Physiol.32(8)640-648(2005) 3.Müller , S., K?nig, I., Meyer, W., et al.Inhibition of vascular oxidative stress in hypercholesterolemia by eccentric isosorbide mononitrateJ. Am. Coll. Cardiol.44(3)624-631(2004) 4.Fan, P.-C., Ma, H.-P., Jiang, W., et al.Anti-hypoxia activity of the novel NO donor acetyl ferulic isosorbide mononitrate in acute high-altitude hypoxia miceBiol. Pharm. Bull.38(9)1280-1289(2015)
| Cas No. | 16051-77-7 | SDF | |
| 别名 | 单硝酸异山梨酯; Isosorbide-5-mononitrate | ||
| Canonical SMILES | O=[N+]([O-])O[C@H]1[C@](OC[C@@H]2O)([H])[C@]2([H])OC1 | ||
| 分子式 | C6H9NO6 | 分子量 | 191.14 |
| 溶解度 | DMSO: ≥ 100 mg/mL (523.18 mM); Water: 50 mg/mL (261.59 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 5.2318 mL | 26.1588 mL | 52.3177 mL |
| 5 mM | 1.0464 mL | 5.2318 mL | 10.4635 mL |
| 10 mM | 0.5232 mL | 2.6159 mL | 5.2318 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet